|
Monday, June 3, 2024, 7:00 AM – 8:00 AM Central Time (8:00 AM – 9:00 AM Eastern Time)
RTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal CancerA CME-Accredited Virtual Event Held in Conjunction with the 2024 ASCO Annual MeetingJoin us on Monday, June 3rd for this CME-accredited webinar Faculty
Scott Kopetz, MD, PhD Professor Deputy Chair for Translational Research Department of Gastrointestinal Medical Oncology Associate Vice President for Translational Integration The University of Texas MD Anderson Cancer Center Houston, Texas John Strickler, MD Associate Professor Associate Director, Clinical Research – GI Duke University Durham, North Carolina
Moderator
Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from Bristol Myers Squibb and Natera Inc. Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Monday, June 3, 2024
Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement Content Validation and Disclosures FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Kopetz — Consulting Agreements: Agenus Inc, Amgen Inc, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Carina Biotech, Flame Biosciences, Frontier Medicines, Genentech, a member of the Roche Group, Harbinger Health, Kestrel Therapeutics, Lutris Pharma, Merck, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Replimune, Revolution Medicines, Roche Laboratories Inc, Tachyon Therapeutics, Tempus, Zentalis Pharmaceuticals; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BridgeBio, Cardiff Oncology, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Guardant Health, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Sanofi, Zentalis Pharmaceuticals. Dr Strickler — Advisory Committees: AbbVie Inc, Agenus Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Natera Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Xilio Therapeutics; Contracted Research: AbbVie Inc, Amgen Inc, A*STAR D3, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Novartis, Pfizer Inc, Revolution Medicines; Data and Safety Monitoring Boards/Committees: AbbVie Inc, BeiGene Ltd, GSK, Pfizer Inc; Stock Options — Private Company: Triumvira Immunologics. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporter |